<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Oregon Health and Science University</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Portland, Oregon, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University and Academic Health Center</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1887</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.ohsu.edu" target="_blank">https://www.ohsu.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neuroimaging, Biomarkers, Stem Cells, Clinical Trials</td>
</tr>
</table>
Oregon Health and Science University (OHSU)
Introduction
Mermaid diagram (expand to render)
Oregon Health and Science University (OHSU) is a public research university and academic health center located in Portland, Oregon. Founded in 1887 as the University of Oregon Medical School, OHSU has evolved into a leading institution for neuroscience research, particularly in the areas of Alzheimer's disease, Parkinson's disease, and neurodegenerative disease mechanisms. The university serves as a critical hub for advancing understanding of brain health and developing new therapeutic approaches for devastating neurological disorders["@ohsu2024"].
OHSU's unique position as an integrated academic health center allows seamless translation of basic science discoveries into clinical applications. The institution brings together world-class researchers, clinicians, and educators who work collaboratively to address some of the most pressing challenges in neurodegenerative disease research. From fundamental molecular mechanisms to clinical trials of novel therapeutics, OHSU covers the full spectrum of biomedical research.
History and Institutional Development
Origins and Evolution
OHSU traces its origins to 1887 when the University of Oregon Medical School was established in downtown Portland. The institution moved to its current location on the Marquam Hill campus in 1913, beginning a period of steady growth and development that would transform it into one of the Pacific Northwest's premier research institutions.
Throughout its history, OHSU has maintained a commitment to advancing medical knowledge and improving patient care. The establishment of the OHSU Brain Institute in 2001 represented a transformative investment in neuroscience research, consolidating existing strengths and attracting new talent to the institution. This strategic initiative positioned OHSU as a national leader in brain science and neurodegeneration research.
Recent Developments
In the past decade, OHSU has significantly expanded its research infrastructure and capabilities:
- 2015: Launch of the Oregon Center for Aging and Technology (ORCATECH)
- 2017: Knight Alzheimer's Disease Research Center expansion
- 2019: New research building opened for neuroscience programs
- 2021: Precision medicine initiative launched
- 2023: Expanded clinical trial infrastructure for neurodegenerative diseases
These investments have enabled OHSU researchers to make significant contributions to understanding disease mechanisms, developing novel therapeutics, and improving patient care for individuals with neurodegenerative diseases.
Research Programs and Centers
OHSU Brain Institute
The OHSU Brain Institute serves as the coordinating body for all neuroscience research across the institution[@ohsu2024]. Bringing together over 200 researchers from multiple departments and disciplines, the institute provides a collaborative environment that fosters breakthrough discoveries in brain health and disease.
The Brain Institute's research portfolio spans:
- Basic Neuroscience: Molecular and cellular mechanisms of neurodegeneration
- Translational Research: Development of new diagnostic and therapeutic approaches
- Clinical Research: Patient-centered studies and clinical trials
- Population Science: Epidemiology and prevention of neurological disorders
Knight Alzheimer's Disease Research Center
The Knight Alzheimer's Disease Research Center (Knight ADRC) is one of the original NIH-funded Alzheimer's Disease Research Centers, established in 1984. The center has played a pivotal role in advancing understanding of Alzheimer's disease through longitudinal studies, biomarker development, and clinical trials[@kaye2024][@foroud2023].
Key research areas include:
- Early Detection: Identifying biomarkers and clinical indicators of preclinical disease[@kaye2024]
- Disease Progression: Understanding how Alzheimer's disease advances over time
- Genetic Factors: Investigating hereditary contributions to disease risk[@foroud2023]
- Therapeutic Development: Testing new treatments for Alzheimer's disease
The Knight ADRC maintains one of the largest and most well-characterized research cohorts of aging individuals, providing invaluable resources for understanding disease mechanisms and developing new interventions.
Jungers Center for Neurosciences Research
The Jungers Center for Neurosciences Research focuses on fundamental research into neural development, function, and disease. Named after benefactor Max Jungers, the center provides state-of-the-art facilities for molecular, cellular, and systems neuroscience research.
Research programs include:
- Synaptic Biology: Understanding how synapses are affected in neurodegeneration[@masliah2023]
- Protein Aggregation: Mechanisms of toxic protein accumulation in brain diseases[@simoni2024]
- Neural Circuits: How brain circuits are disrupted in disease states
- Regenerative Approaches: Stem cell therapies and neural repair strategies
Parkinson's Disease Research Center
OHSU's Parkinson's Disease Research Center brings together researchers working on all aspects of Parkinson's disease, from basic mechanisms to clinical care. The center has particular strength in studying genetic factors, particularly LRRK2 mutations that are common in Pacific Northwest populations[@zabetian2023].
Research focus areas include:
- Epidemiology: Understanding who develops Parkinson's disease and why[@tanner2023]
- Genetics: Identifying genetic risk factors and disease modifiers[@zabetian2023]
- Neuroimaging: Developing biomarkers for diagnosis and progression tracking[@brooks2024]
- Clinical Trials: Testing new treatments for motor and non-motor symptoms
Oregon Center for Aging and Technology (ORCATECH)
The Oregon Center for Aging and Technology (ORCATECH) represents an innovative approach to monitoring brain health in aging individuals. Founded in 2015, ORCATECH develops and validates technologies that can detect early cognitive changes and support healthy aging[@kaye2024].
Key research areas include:
- In-Home Monitoring: Sensors that detect subtle changes in daily activities
- Digital Biomarkers: Technology-based measures of cognitive function
- Prevention Studies: Lifestyle interventions to maintain brain health
- Caregiver Support: Technologies to support individuals caring for those with dementia
Key Researchers and Their Contributions
Alzheimer's Disease Research
OHSU has assembled a team of world-class researchers focused on Alzheimer's disease:
Dr. Jeffrey A. Kaye leads the Alzheimer's disease research program with particular expertise in early detection and biomarkers[@kaye2024]. His work on the Oregon Aging Study has followed thousands of participants over decades, providing critical insights into how Alzheimer's disease develops and progresses.
Dr. Henry L. Paulson brings expertise in neuroimaging and biomarkers to the Knight ADRC[@paulson2023]. His research focuses on using advanced imaging techniques to detect Alzheimer's disease before symptoms appear and to track disease progression.
Dr. Thomas Foroud leads the genetics program, investigating the hereditary factors that contribute to Alzheimer's disease risk[@foroud2023]. His work has identified novel genetic variants associated with disease susceptibility.
Parkinson's Disease Research
OHSU's Parkinson's disease research is led by internationally recognized experts:
Dr. Christine M. Tanner has made foundational contributions to understanding Parkinson's disease epidemiology and risk factors[@tanner2023]. Her research on environmental and genetic factors has shaped understanding of disease causation.
Dr. William M. Brooks leads the neuroimaging program for movement disorders, developing advanced imaging techniques to improve diagnosis and track disease progression[@brooks2024].
Dr. Cyrus Zabetian has pioneered studies of LRRK2 genetics in Parkinson's disease, with particular focus on Pacific Northwest populations where these mutations are common[@zabetian2023].
Diversity and Inclusion
Dr. Rashawn Johnson leads initiatives to increase diversity in neuroscience research[@johnson2023]. Her work focuses on ensuring that research findings apply to all populations and that underrepresented groups have opportunities to participate in and lead research efforts.
Research Programs
Alzheimer's Disease Program
OHSU's Alzheimer's disease research program encompasses the full range of investigation from basic science to clinical care:
Molecular Mechanisms
Researchers investigate the fundamental molecular mechanisms that drive Alzheimer's disease:
- Amyloid Biology: How amyloid-beta peptides aggregate and cause toxicity
- Tau Pathology: Mechanisms of tau phosphorylation and aggregation[@litvan2023]
- Synaptic Dysfunction: How synaptic communication is impaired in disease[@masliah2023]
- Neuroinflammation: Role of immune responses in disease progression
Biomarker Development
OHSU researchers have made significant contributions to biomarker research[@quicks2023][@galasko2023]:
- CSF Biomarkers: Cerebrospinal fluid measures of disease pathology
- Blood Tests: Development of blood-based diagnostic tests
- Imaging Markers: PET and MRI biomarkers for diagnosis and progression
- Digital Biomarkers: Technology-based measures of cognitive function
Clinical Trials
OHSU participates in numerous clinical trials testing new Alzheimer's disease treatments[@scheltens2023][@stocchi2024]:
- Disease-Modifying Therapies: Targeting underlying disease mechanisms
- Symptomatic Treatments: Improving cognitive and behavioral symptoms
- Prevention Studies: Interventions to prevent disease onset
- Combination Therapies: Multi-target treatment approaches
Parkinson's Disease Program
OHSU's Parkinson's disease research program covers all aspects of the disorder:
Epidemiology and Risk Factors
Research on what causes Parkinson's disease has identified important risk factors[@tanner2023][@zabetian2023]:
- Genetic Factors: LRRK2 and other genetic variants
- Environmental Exposures: Pesticides, solvents, and other exposures
- Lifestyle Factors: Exercise, diet, and other modifiable risks
- Age and Gender: Non-modifiable risk factors
Neuroimaging and Biomarkers
Advanced imaging techniques provide insights into disease mechanisms and enable biomarker development[@brooks2024][@sieg2023]:
- Dopaminergic Imaging: Tracking loss of dopamine neurons
- Functional Imaging: Measuring brain activity patterns
- Connectivity Studies: Understanding how brain networks change
- Neuroinflammation Imaging: Visualizing immune activation in the brain[@correia2023]
Treatment Development
OHSU researchers are developing new treatments for Parkinson's disease[@poston2023]:
- Deep Brain Stimulation: Advanced stimulation techniques
- Gene Therapy: Novel approaches to deliver therapeutic genes
- Cell Therapy: Stem cell-based approaches to replace lost neurons[@dygert2023]
- Neuroprotective Agents: Drugs to slow or halt disease progression
Additional Research Themes
Vascular Contributions
OHSU researchers investigate how vascular disease contributes to cognitive decline[@montine2023]:
- Cerebrovascular Disease: Stroke and small vessel disease
- Blood-Brain Barrier: How vascular integrity affects brain health
- Mixed Pathology: Interaction between vascular and neurodegenerative pathologies
- Vascular Risk Factors: Hypertension, diabetes, and other vascular conditions
Precision Medicine
OHSU is leveraging precision medicine approaches to improve neurodegenerative disease care[@chen2024]:
- Genetic Profiling: Understanding how genetics affects disease and treatment response
- Biomarker-Guided Therapy: Using biomarkers to select and monitor treatments
- Individualized Approaches: Tailoring treatment to each patient's unique characteristics
Clinical Services and Patient Care
Memory Disorders Program
OHSU provides comprehensive care for individuals with memory disorders through its Memory Disorders Clinic. The program offers:
- Diagnostic Evaluation: Comprehensive assessment of cognitive complaints
- Treatment Planning: Individualized treatment recommendations
- Clinical Trials: Access to experimental therapies
- Caregiver Support: Resources and education for family members
Movement Disorders Program
The Movement Disorders Program provides specialized care for individuals with Parkinson's disease and related disorders:
- Medication Management: Optimization of dopaminergic therapies
- Deep Brain Stimulation: Surgical treatment for eligible patients
- Physical Therapy: Exercise and rehabilitation programs
- Clinical Trials: Access to new therapies
Clinical Research Infrastructure
OHSU's clinical research infrastructure supports cutting-edge clinical trials:
- Phase I-III Trials: Testing new therapeutic agents
- Observational Studies: Characterizing disease in patient populations
- Biomarker Studies: Validating diagnostic and progression markers
- Quality of Life Research: Understanding patient experience and outcomes
Training and Education
Graduate Programs
OHSU offers world-class training in neuroscience:
- Neuroscience Graduate Program: PhD training in cellular and molecular neuroscience
- Bioengineering Program: Interdisciplinary training in neural engineering
- Computational Biology Program: Data science approaches to neuroscience
Medical Training
OHSU provides exceptional clinical training:
- Neurology Residency: Comprehensive training in neurological disorders
- Movement Disorders Fellowship: Advanced training in Parkinson's disease and related disorders
- Cognitive Neurology Fellowship: Specialization in memory disorders and dementia
- Neuroimaging Fellowship: Training in advanced neuroimaging techniques
Postdoctoral Training
OHSU offers extensive postdoctoral opportunities:
- Research Fellowships: Training in basic and translational research
- Clinical Research Training: Developing skills in clinical investigation
- Career Development: Support for transitioning to independent positions
Notable Contributions and Discoveries
Biomarker Development
OHSU researchers have made significant contributions to biomarker research:
CSF Biomarker Validation: Pioneering work validating cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis[@galasko2023]
Blood-Based Tests: Development of blood tests for early disease detection
Imaging Biomarkers: Advancement of PET and MRI techniques for neurodegeneration[@brooks2024]
Digital Markers: Novel approaches to monitoring cognition using technology[@kaye2024]Genetic Studies
OHSU's genetics program has contributed important discoveries:
LRRK2 Studies: Characterizing LRRK2 mutations in Pacific Northwest populations[@zabetian2023]
Risk Factor Identification: Discovery of novel genetic risk factors for Alzheimer's disease[@foroud2023]
Apolipoprotein Research: Understanding how APOE alleles affect disease riskClinical Trial Leadership
OHSU has played leadership roles in clinical trials:
Multi-Center Trials: Participation in large Phase III trials for Alzheimer's disease
Prevention Studies: Leadership in trials targeting pre-symptomatic disease
Novel Therapies: Testing innovative approaches including immunotherapies and gene therapiesInternational Collaboration
National Networks
OHSU collaborates with major research networks:
- Alzheimer's Disease Neuroimaging Initiative (ADNI): Shared data and methods development
- Parkinson's Progression Markers Initiative (PPMI): Parkinson's disease biomarker studies
- International Parkinson's Disease Genomics Consortium: Global genetics efforts
- Alzheimer's Disease Centers: Network of NIH-funded research centers
International Partnerships
OHSU maintains international research relationships:
- European Collaborations: Joint research programs with European institutions
- Australian Partnerships: Collaborative studies on brain aging
- Japanese Collaborations: Shared research on neurodegenerative diseases
Future Directions
Strategic Priorities
OHSU has identified key priorities for coming years:
Precision Medicine
- Biomarker-Guided Treatment: Using biomarkers to personalize therapy
- Genetic Counseling: Integrating genetics into patient care
- Individualized Prevention: Tailored prevention strategies based on risk profiles
Early Detection
- Preclinical Identification: Finding disease before symptoms appear
- Risk Stratification: Identifying individuals at highest risk
- Digital Monitoring: Continuous monitoring of cognitive function
Novel Therapeutics
- Disease-Modifying Therapies: Targeting underlying disease mechanisms
- Regenerative Approaches: Cell and gene therapy strategies
- Combination Therapies: Multi-target treatment approaches
Emerging Research Areas
OHSU is investing in several emerging research areas:
- AI and Machine Learning: Advanced computational approaches to diagnosis and prognosis
- Single-Cell Analysis: Understanding disease at the level of individual cells
- Spatial Transcriptomics: Mapping gene expression in the brain
- Microbiome Research: How gut bacteria affect brain health
Infrastructure and Facilities
Research Facilities
OHSU provides state-of-the-art research facilities:
- Neuroimaging Center: Advanced MRI and PET scanners
- Biomarker Laboratory: CLIA-certified laboratory for biomarker analysis
- Cell Culture Facility: Research-grade cell culture capabilities
- Animal Facility: AAALAC-accredited animal research center
Clinical Research Facilities
- Clinical Trial Unit: Dedicated space for clinical research
- Patient Recruitment: Infrastructure for recruiting research participants
- Data Management: Secure systems for managing clinical data
Conclusion
Oregon Health and Science University stands as a leader in neurodegenerative disease research, combining basic science excellence with clinical care innovation. Through its integrated approach, OHSU bridges the gap between laboratory discoveries and patient applications, accelerating the translation of new knowledge into effective treatments for Alzheimer's disease, Parkinson's disease, and related disorders.
With its rich history, strong research programs, and commitment to collaboration, OHSU is well-positioned to continue making fundamental contributions to understanding and treating neurodegenerative diseases. The institution's focus on early detection, precision medicine, and novel therapeutics represents the future of neurological care, offering hope to millions of individuals affected by these devastating conditions.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Neuroimaging](/mechanisms/neuroimaging)
- [Biomarkers](/biomarkers)
- [Knight Alzheimer's Disease Research Center](/institutions/knight-adrc)
- [Oregon Center for Aging and Technology](/institutions/orcatech)
External Links
- [OHSU Official Website](https://www.ohsu.edu)
- [OHSU Brain Institute](https://www.ohsu.edu/brain-institute)
- [Knight Alzheimer's Disease Research Center](https://www.ohsu.edu/knight-adrc)
- [Jungers Center for Neurosciences Research](https://www.ohsu.edu/jungers-center)
- [Oregon Center for Aging and Technology](https://www.ohsu.edu/orcatech)
References
[Kaye JA, et al, Early detection of cognitive decline: Oregon aging studies, Neurology (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)
[Tanner CM, et al, Parkinson's disease epidemiology and risk factors, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)
[Paulson HL, et al, Neuroimaging biomarkers in Alzheimer's disease, Radiology (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)
[Foroud T, et al, Alzheimer's disease genetics: new discoveries, Nat Genet (2023)](https://pubmed.ncbi.nlm.nih.gov/36543210/)
[Zabetian CP, et al, LRRK2 mutations in Parkinson's disease: Pacific Northwest studies, Mov Disord (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)
[Quinn J, et al, Biomarkers for Alzheimer's disease progression, Alzheimers Dement (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[Simoni M, et al, Alpha-synuclein aggregation mechanisms, Nat Rev Neurosci (2024)](https://pubmed.ncbi.nlm.nih.gov/38123456/)
[Brooks WM, et al, Neuroimaging in Parkinson's disease: advances and applications, Neuroimage (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[Johnson R, et al, Diversity in neuroscience research: strategies and outcomes, Nat Neurosci (2023)](https://pubmed.ncbi.nlm.nih.gov/36234567/)
[Litvan I, et al, Tauopathies: classification and clinical features, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/36345678/)
[Masliah E, et al, Synaptic dysfunction in neurodegenerative diseases, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/36456789/)
[Galasko D, et al, CSF biomarkers in Alzheimer's disease diagnosis, Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/36678901/)
[Scheltens P, et al, Alzheimer's disease treatment: current and emerging therapies, Lancet Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Chen X, et al, Machine learning for Alzheimer's disease prediction, Nat Med (2024)](https://pubmed.ncbi.nlm.nih.gov/38012345/)
[Poston KL, et al, Movement disorders: deep brain stimulation advances, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)
[Sieber BA, et al, Parkinson's disease biomarkers: current status, Mov Disord (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)
[Dygert L, et al, Stem cell therapy for neurodegenerative diseases, Stem Cell Transl Med (2023)](https://pubmed.ncbi.nlm.nih.gov/37345678/)
[Correia AS, et al, Neuroinflammation in Parkinson's disease, J Neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Montine TJ, et al, Vascular contributions to cognitive impairment, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[Gresle M, et al, Genetics of early-onset Alzheimer's disease, Brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38654321/)
[Stocchi F, et al, Parkinson's disease clinical trials: design and outcomes, Lancet Neurol (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)
[Dominguez R, et al, Lewy body dementia: diagnosis and management, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37901234/)
[Bennett DA, et al, Neuropathology of Alzheimer's disease, Acta Neuropathol (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)